On November 14, 2018, the subscription period for NeoDynamics AB (publ) (”NeoDynamics”) issue of units of initially approx. SEK 50.5 million prior to listing on Spotlight Stock Market (“Spotlight”) was completed. The issue of units was subscribed to approx. SEK 44.9 million, equating to a subscription ratio of approx. 89 percent prior free guarantee subscription of approx. SEK 5.6 million from the company’s principal shareholder. Through the issue of units, NeoDynamics is allocated approx. SEK 50.5 million before issue costs, which amounts to approx. SEK 2.5 million. Through the issue of units, NeoDynamics will receive approx. 750 new shareholders. The first day of trading on Spotlight is expected to be December 7, 2018. Through the completed issue of units, the company has been given the necessary capital to continue its development of NeoNavia towards a commercial version and market launch.
Anna Eriksrud, CEO at NeoDynamics, comments
“I would like to express my gratitude to all those who showed interest in NeoDynamics and chose to subscribe for units – and thereby becoming a part in the fight against breast cancer. With the capital we are now provided with, we stand financially strong ahead of our continued journey to complete the development of NeoNavia into a commercial product. In the nearby future, we will complete a final prototype of NeoNavia and initiate our clinical studies in Germany and the United Kingdom. I look forward to NeoDynamics' continued development and to manage the confidence shown by both new and existing owners!”
Subscriptions and allotment
The issue of units was subscribed to approx. SEK 44.9 million, including presubscription commitments, corresponding to a subscription ratio of approx. 89 percent. Approximately SEK 5.6 million, corresponding to approx. 11 percent of the total issue, is therefore allocated to the company’s principal shareholder Boai NKY Medical Holdings Ltd who has given a free guarantee subscription. Through the issue, 6 160 000 shares and 3 080 000 series TO 1 warrants are emitted. NeoDynamics is thereby provided with approx. SEK 50,5 million before issue costs, which amounts to approx. SEK 2,5 million. Settlement notes are scheduled to be sent to all allotted subscribers today, November 19, 2018. Last day for subscribers to pay the issue funds is November 23, 2018.
First day of trading and market making
The first day of trading in NeoDynamics’ shares and series TO 1 warrants on Spotlight is expected to be December 7, 2018. The shares will be traded under the ticker "NEOD" with ISIN code SE0011563410. The series TO 1 warrants will be traded under the ticker "NEOD TO 1" with ISIN code SE0011725605. Prior to the planned listing, NeoDynamics has appointed Sedermera Fondkommission as market maker for the company's share. The market maker assignment will be initiated in connection with the company's planned listing on Spotlight. In its market maker assignment, Sedermera Fondkommission will continuously place trading posts on both the buy- and sell side in the order book of NeoDynamics' share and ensure that a predetermined spread is held in the share. The purpose of the market making is to promote a good liquidity and ensure a low spread between buying and selling prices in the trade.
Number of shares, warrants and share capital
When NeoDynamics’ issue of units has been registered at Bolagsverket, the total number of shares will amount to 15,303,520 and the share capital will amount to SEK 1,530,352.00. Furthermore, there will be 3,080,000 outstanding series TO 1 warrants.
Sedermera Fondkommission is the financial advisor and issuing agency to NeoDynamics in connection with the issue of units and the planned listing on Spotlight Stock Market. Nordnet Bank AB is acting as Selling Agent in the issue of units.
For further information about the IPO and the planned listing, please contact:
Telephone: +46 (0) 40-615 14 10
For further information about NeoDynamics, please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ)
Telephone: +46 8 522 79 667
This press release contains information that NeoDynamics AB (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on November 19, 2018.
Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, NeoDynamics have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.